ABO-101
Rare Genetic Disease (Liver-targeted)
Phase 1/2Active
Key Facts
Indication
Rare Genetic Disease (Liver-targeted)
Phase
Phase 1/2
Status
Active
Company
About Arbor Biotechnologies
Arbor Biotechnologies is a private, pre-revenue biotech firm pioneering next-generation CRISPR-based gene editing technologies. The company has built a wholly owned portfolio of proprietary DNA editors capable of addressing over 90% of the human genome, which it is leveraging to develop bespoke genetic medicines. With a lead program, ABO-101, advancing through regulatory milestones and strategic partnerships with Vertex Pharmaceuticals, Chiesi Group, and others, Arbor is positioned to pursue functional cures for rare and common diseases. The company is backed by significant venture capital, including a $215M Series B and a $74.9M Series C financing.
View full company profile